She wrote to a scientist about her

fatigue. It inspired a
breakthrough.
Her dogged efforts lead to a new scientific
discovery that may help others with long covid
and other chronically fatiguing illnesses

Amanda Twinam and her daughter, Paige. Research on Twinam's fatigue may help shed light on long
covid and other conditions. (Ashley Brown)
:
 Save

Amanda Twinam’s journey to understand her decades-long fatigue

began with a breast cancer diagnosis at age 28. Twinam underwent a
mastectomy before enduring chemotherapy. The medicines made her
sick and triggered seizures, which eventually brought her to a
rheumatologist.

That doctor found a marker for autoimmune diseases in Twinam’s blood.

And yet, none of the proposed diagnoses fully fit. “Fatigue was my
primary complaint, sometimes my only complaint,” says Twinam, who’d
:
 had a bout of suspected mononucleosis in high school that left her
exhausted for months. “But no one knew what to do.”

In 2015, after further testing, Twinam, now 44, was found to carry a
genetic cancer disorder, Li-Fraumeni syndrome. A second breast cancer
diagnosis shortly followed, and Twinam underwent another
mastectomy. But Twinam knew that something else was wrong.

Story continues below advertisement

As she moved into her 40s, she was having increasing trouble standing
and walking. The Albany, N.Y., lawyer scaled back to part-time work, as
she couldn’t keep up with her legal cases while raising a young daughter.

“I was a decreasingly functional human and had no great explanation for

it, which made me feel crazy,” she says. “Doctors didn’t “know what to
do with me.” So Twinam undertook a years-long journey to understand
her continuing fatigue, neuropathy, muscle weakness and other
problems.

Her dogged efforts led to a new scientific discovery at the National

Institutes of Health and a promising new line of research that may end
up helping many other people with chronically fatiguing illnesses,
possibly including long covid.

“We’re very excited about trying” drugs to treat the problem identified
in Twinam, said Paul Hwang, an NIH researcher who led the work.

Story continues below advertisement

The red flags that Twinam had an unrecognized chronic illness began
after her suspected case of mono in high school. She says she feels she
never fully recovered. One big tell: In college, after exercising, Twinam
would not experience an endorphin rush. Instead, she told her friends
:
 she “felt like garbage.”

Between her two breast cancers, Twinam decided to go back to school

for a master’s degree in public health. She wanted to understand
biostatistics on the path to understanding herself.

“I was genuinely more excited when I got a 100 on a biology midterm

than when I passed the bar,” she says.

She thought anxiety and drinking made her ill. The truth was scarier.

In 2016, she was intrigued by a journal article about Li-Fraumeni

syndrome written by Hwang. The article described problems with
mitochondria — the famous powerhouses of cellular biology, small
tubelike structures inside cells that produce the energy we need to live.

Story continues below advertisement

In people with this cancer syndrome, Hwang’s lab had found that
mitochondria produce too much energy, which cancer cells gobble up as
they metastasize. Twinam wondered whether her specific version of Li-
Fraumeni syndrome could lead to the opposite problem, too little
energy?

Twinam began a message to Hwang that proved pivotal: “I read with

interest your recent article on inhibiting mitochondrial respiration in a
mouse model of Li-Fraumeni Syndrome.”

“I had zero expectations,” Twinam says. “Here’s me sending an email to

this fancy science researcher who isn’t going to give me the time of day.”

Hwang, who runs a laboratory at the National Heart, Lung and Blood
Institute, responded the next day. He wrote: “Yes, I agree with you, it is
possible that [your version of Li Fraumeni Syndrome] may be altering
metabolism and causing your fatigue symptoms.”
:
 Hwang was wrong — Twinam’s energy problems had nothing to do with
Li-Fraumeni syndrome. But it would take Hwang and colleagues years of
benchwork, including making genetically modified “Amanda mice,” to
understand this.

Story continues below advertisement

“Amanda showed up and she challenged us,” says Hwang during an

interview in his office. “So we dug.”

Hwang brought Twinam to Bethesda in 2017. During a battery of tests, a

curious result popped up. Twinam’s calf muscle took a long time to
replenish an energy-carrying molecule after a short exercise session. In
other patients with Li-Fraumeni syndrome, this molecule regenerates in
an average of 35 seconds. In Twinam, it took 80 seconds.

“We never see it that delayed,” Hwang says.

Puzzled, Hwang flew Twinam’s brother and father to Maryland, as they

both also carried a gene for Li-Fraumeni. But on the energy-production
test, the two men showed quick energy rebound, unlike Amanda.
Neither of them had ever complained of serious fatigue, either.

Story continues below advertisement

Hwang now had strong evidence that Twinam’s energy problems — both
at the cellular and the human level — were caused by something other
than Li-Fraumeni. But what?

Around the same time, in 2017, Hwang received another serendipitous

correspondence. NIH researcher Brian Walitt had heard Hwang was
studying energy production inside mitochondria.

Walitt was interested because he was orchestrating an intensive study

on a small number of inpatients at NIH’s research hospital who were
:
 diagnosed with chronic fatigue syndrome, also known as myalgic
encephalomyelitis or ME/CFS. (I was a patient in this study and Hwang
also used my data in his research.)

Story continues below advertisement

This contact sparked Hwang’s curiosity: What if this unusual cancer

syndrome patient also had an illness, such as ME/CFS, that causes
chronic fatigue?

Hwang began a detailed biochemical search. He found that skin cells

taken from Twinam appeared to be churning out an excess of a protein
called WASF3. Zooming inside Twinam’s mitochondria, Hwang and
colleagues eventually saw something stunning: Like a stick jammed into
bicycle spokes, the overabundant protein was literally gumming up the
gears of energy production.

“It’s really striking,” Hwang says.

Mitochondria make energy by a process called respiration, spinning

oxygen and glucose into energy-carrying molecules. At the center of this
chemical chain reaction is an 800-pound biochemical gorilla called the
supercomplex.

Story continues below advertisement

The protein Twinam made too much of? It rudely jams up the
supercomplex. “It’s making this whole thing disassemble,” Hwang says.
“It’s literally falling apart.”

Extensive lab work confirmed and extended the finding. In dishes of

cells, amping up WASF3 turned down cellular energy production.
Tamping it down led to more energy. Mice bred to make too much of the
protein pooped out quickly, like Twinam does, and will walk on a
:
 treadmill about half as long as normal mice.

A final serendipity broadened Hwang’s research from a single patient to

an entire population of sick people: He obtained muscle tissue from
Walitt’s ME/CFS patients.

Nine out of 14 had similar overabundance of WASF3 as Twinam, and, on

average, the group’s levels of this protein were higher than that of
healthy volunteers. Although the sample size is small, the finding
suggests that this energy-squashing problem is widespread in ME/CFS.

Story continues below advertisement

The research triggered by Twinam culminated in August with a

publication from Hwang and colleagues in the journal PNAS. Scientists
in the small field of ME/CFS research are excited by the discovery, which
points to a potential — and badly needed — treatment strategy.

“It was done very elegantly,” says Mady Hornig, who also studies
ME/CFS as a physician-researcher at Columbia University’s Mailman
School of Public Health. “It’s not very common that we do all of these …
steps, having doctors who are really persistent about what is happening
with one individual and applying a scientific lens.”

ME/CFS is common — up to 2.5 million Americans have it, according to a

2015 Institute of Medicine Report — but also commonly misunderstood.

Research funding has been scarce. Diagnosis is often delayed or never

arrives. The pandemic has dramatically added to the ranks of people
with ME/CFS, as studies find that up to half of people with long covid
qualify for that diagnosis. There are no blood tests to identify the
disorder, no treatments approved by the Food and Drug Administration,
let alone a cure. Up to a quarter of all ME/CFS patients are bed bound.
:
 For Hwang, developing a treatment for the illness is now “what keeps
me going.” His small laboratory, just four scientists, is planning a clinical
trial with a drug that recently came onto the market for another disease.

“Amazing findings in medicine are sometimes based on one patient,” he

says.

As for Twinam, after decades of feeling ill with no diagnosis that ever
made sense, she believes her own story has finally been legitimized, and
in a major scientific journal at that.

“There’s this difference between cancer and chronic fatigue syndrome,”

a diagnosis her rheumatologist has finally added to her file, she says.
“Everybody believes you when you have cancer. You joke about having a
‘cancer card’ to get off from doing things. No one is handing out CFS
cards. I can finally say, ‘It’s not psychological. I’m not a malingerer.’ We
now have a scientific explanation.”

Sign up for the Well+Being newsletter, your source of expert advice and
simple tips to help you live well every day
: